中国卵巢癌患者与健康对照者的BRCA胚系突变非选择性全国队列研究
该研究采用二代测序在中国非选择性卵巢癌患者(n=1331)与健康对照(n=1763)中筛查BRCA胚系有害突变。患者中BRCA1有害突变占17.1%(227例)、BRCA2占5.3%(70例),对照中分别为0.3%(6例)和0.1%(2例)。作者推荐对所有中国卵巢癌患者及有遗传性乳腺卵巢癌相关癌症家族史的一般人群进行BRCA检测。
要点
- 中国卵巢癌患者BRCA1有害突变占17.1%,BRCA2占5.3%。
- 健康对照BRCA1有害突变占0.3%,BRCA2占0.1%。
- 作者推荐所有中国卵巢癌患者及有HBOC相关癌症家族史者行BRCA检测。
核心结论
- 作者推荐对所有中国卵巢癌患者以及有遗传性乳腺卵巢癌相关癌症(HBOC相关癌症)家族史的一般中国人群进行BRCA检测。
- 携带变异者不仅可从卵巢癌早期预防中获益,也可从医疗管理中获益。
研究设计与样本
- 采用二代测序对中国非选择性卵巢癌患者(n=1331)与健康对照(n=1763)进行BRCA胚系有害突变筛查,并描述BRCA有害变异的类型与谱系。
主要发现
- 1331例卵巢癌患者中,227例(17.1%)携带BRCA1有害变异,70例(5.3%)携带BRCA2有害变异。
- 1763例对照中,6例(0.3%)携带BRCA1有害变异,2例(0.1%)携带BRCA2有害变异。
- 无患者同时携带BRCA1和BRCA2突变。
- 共鉴定出63个新突变,并报道了三个中国特异性热点突变:BRCA1 c.5470_5477delATTGGGCA、BRCA1 c.981_982delAT和BRCA1 c.3770_3771delAG。
- 这些高频复发突变均分布在外显子10上,可能也是中国卵巢癌BRCA突变的独特特征。
临床怎么用
- 作者推荐对所有中国卵巢癌患者进行BRCA检测。
- 作者推荐对有HBOC相关癌症家族史的一般中国人群进行BRCA检测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the BRCA status in Chinese patients with ovarian cancer (OC). Though there were two large prevalence studies in Chinese OC patients, this was the first time to observe it in healthy controls. METHODS: We performed BRCA mutation screening using next-generation sequencing to determine the prevalence of BRCA germline deleterious mutations in an unselected cohort of Chinese OC patients (n = 1331) versus healthy controls (n = 1763) and describe the types and spectrum of BRCA deleterious variants. RESULTS: Among the 1331 patients with OC, 227 (17.1%) carried deleterious variants in BRCA1 and 70 (5.3%) carried deleterious variants in BRCA2. Of 1763 control subjects, 6 (0.3%) and 2 (0.1%) had deleterious variants in BRCA1 and BRCA2. No patient carried mutations in both BRCA1 and BRCA2 simultaneously. Sixty-three novel mutations were identified, and three Chinese specific hot-spot mutations were notified as BRCA1 c.5470_5477delATTGGGCA, BRCA1 c.981_982delAT, and BRCA1 c.3770_3771delAG. Interestingly, all these high-frequency recurrent mutations were distributed on exon 10, which may also be the Chinese OC BRCA mutations' distinct characteristics. In addition, in our study, the estimated odds ratio (OR) of OC associated with BRCA1 positive variants were approximately 34.6 (95% CI, 12.5-95.7) in age group under 40 and 42.4 (95% CI, 5.9-305.2) in group older than 50 in the Chinese population, respectively. CONCLUSIONS: We recommend BRCA testing to all Chinese OC patients and those general Chinese who have family members with hereditary breast and ovarian related cancer (HBOC)-related cancers. Variants carriers would not only benefit from early prevention of OC but also for the medical management.
引用
- Li A, Xie R, Zhi Q, et al. BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls. Gynecol Oncol. 2018. PMID: 30078507. doi:10.1016/j.ygyno.2018.07.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。